Stryker raises annual profit forecast on robust demand for medical, surgical devices
Oct 29(Reuters) -Stryker Corp SYK.N slightly raised its annual profit forecast on Tuesday, banking on strong demand for its medical and surgical devices and healthy procedural volumes.
Shares of the Kalamazoo, Michigan-based company rose 3.3% to $367, in after-market hours.
The company now expects annual adjusted profit to range between $12.00 and $12.10 per share, compared to the previous forecast of $11.90 to $12.10 per share. Analysts' average estimate for 2024 is pegged at $12.01, according to data compiled by LSEG.
There has been a significant surge in demand for medical implant devices since last November, as more people in the United States, particularly older adults, opted for surgical treatments that were previously deferred during the pandemic, leading to a boost in procedural volumes.
Sales at Stryker's medical surgery and neurotechnology unit, which makes surgical equipment like endoscopy devices for brain surgeries, rose 12.8% to $3.2 billion, beating analysts' estimate of $3.1 billion.
In the orthopaedics and spine segment, which produces implants for joint replacement surgery, sales rose by 10.7% to $2.3 billion, while analysts had projected $2.2 billion.
The joint-implant maker now expects its 2024 organic net sales growth to be in the range of 9.5% to 10%, adjusting from the earlier forecast of 9% to 10%.
The company reported a quarterly revenue increase of 11.9% amounting to $5.5 billion, compared to analysts' expectations of $5.4 billion.
On an adjusted basis, the company posted a profit of $2.87 per share for the quarter ended September 30, above analysts' estimate of $2.77 per share.
Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by Mohammed Safi Shamsi
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
